Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

Baron, Frédéric; Stevens‐Kroef, Marian; Kiciński, Michal; Meloni, Giovanna; Muus, Petra; Marie, Jean‐Pierre; Halkes, Constantijn J.M.; Thomas, Xavier; Vrhovać, Radovan; Specchia, Giorgina; Lefrère, François; Sica, Simona; Mancini, Marco; Venditti, Adriano; Hagemeijer, Anne; Becker, Heiko; Jansen, Joop H.; Amadori, Sergio; Witte, Théo de; Willemze, R.; Suciu, Stefan

doi:10.1007/s00277-018-3396-4

Cited by 4 publications

(3 citation statements)

References 34 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The monosomal karyotype (MK) was defined as the presence of a chromosomal aberration pattern characterized by at least two autosomal monosomies or one monosomy plus one or more structural aberrations (not including loss of a chromosome) 6,7 . Subclones (SC) were defined as the presence of one to three subclones 8 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse‐risk AML patients

Fuse

Tanaka

Shibasaki

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Chromosome analysis is necessary for the diagnosis and risk classification of acute myeloid leukemia (AML). 1,2 Fragmented chromosomes whose origin cannot be identified from an existing autosomal or sex chromosome may be observed, termed marker chromosome (MC). MC is considered to originate from marked genomic instability. 3 It is a relatively common abnormality, and its incidence in AML was reported to be 6.6%-16.1%. 4,5 However, MC is currently not specifically considered in the risk classifications by the refined Medical Research Council (rMRC) 1 or European Leukemia Net (ELN). 2 Although AML with MC (MC+) has a poor prognosis even after intensive chemotherapy, 4,5 its influence on the outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In addition to MC, complex karyotype (CK), monosomal karyotype (MK), and subclones (SC) are considered to result from genomic instability. CK and MK have been established as independent chromosomal prognostic factors 1,6‐8 and are used clinically.…”

Section: Introductionmentioning

confidence: 99%

Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse‐risk AML patients

Fuse

Tanaka

Shibasaki

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Patients with AML secondary to previous chemotherapy or previous chronic myeloid diseases (i.e., myelodysplastic syndrome or chronic myeloproliferative neoplasia) also have an adverse prognosis, and this is true especially for younger adults [ 50 ]. Another adverse prognostic parameter is the identification of AML subclones at the time of diagnosis [ 52 , 53 , 54 ].…”

Section: Aml Heterogeneity and Prognostic Evaluationmentioning

confidence: 99%

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

Hernandez-Valladares

Bruserud

Selheim

2020

IJMS

View full text Add to dashboard Cite

With the current reproducibility of proteome preparation workflows along with the speed and sensitivity of the mass spectrometers, the transition of the mass spectrometry (MS)-based proteomics technology from biomarker discovery to clinical implementation is under appraisal in the biomedicine community. Therefore, this technology might be implemented soon to detect well-known biomarkers in cancers and other diseases. Acute myeloid leukemia (AML) is an aggressive heterogeneous malignancy that requires intensive treatment to cure the patient. Leukemia relapse is still a major challenge even for patients who have favorable genetic abnormalities. MS-based proteomics could be of great help to both describe the proteome changes of individual patients and identify biomarkers that might encourage specific treatments or clinical strategies. Herein, we will review the advances and availability of the MS-based proteomics strategies that could already be used in clinical proteomics. However, the heterogeneity of complex diseases as AML requires consensus to recognize AML biomarkers and to establish MS-based workflows that allow their unbiased identification and quantification. Although our literature review appears promising towards the utilization of MS-based proteomics in clinical AML in a near future, major efforts are required to validate AML biomarkers and agree on clinically approved workflows.

show abstract

Filled with Desire, Perceive Molecules

Strand

Engen

2022

Human Perspectives in Health Sciences and Technology

View full text Add to dashboard Cite

Could there be a Taoist philosophy of Acute Myeloid Leukaemia (AML)? This chapter discusses why a molecular treatment of AML has been so hard to find but still so intensely researched, and exposes some of the ethical dilemmas involved when treating this aggressive blood cancer. It does so by applying the concepts and style of the ancient Chinese masterpiece Tao Te Ching, the essence of which is that the real world is richer than what can be expressed by language.

show abstract

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

Abstract: AML-10: ClinicalTrials.gov identifier: NCT00002549, retrospectively registered July 19, 2004; AML12: ClinicalTrials.gov identifier: NCT00004128, registered January 27, 2003.

Cited by 4 publications

References 34 publications

Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse‐risk AML patients

Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse‐risk AML patients

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives

Filled with Desire, Perceive Molecules

Contact Info

Product

Resources

About